Atlas Trials

Phase 3 Trial of Elacestrant Versus Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer

Clinical trial NCT03778931 · COMPLETED

Trial details

NCT number
NCT03778931
Sponsor
Stemline Therapeutics, Inc.
Status
COMPLETED
Phase
Phase 3
Study type
INTERVENTIONAL
Breast Cancer
Start date
2019-05-10
Primary completion
2021-08-24
Enrollment
478

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.